I often discuss the good and the bad in the news. But I thought it would be great to start 2017 with just the good! The SWOG 0777 trial results, recently published in The Lancet, and serum Freelite testing, just published in Blood, will help day-to-day care of myeloma patients in a variety of ways. Both studies are considered important and have accompanying commentaries or editorials in the journals reflecting that. In a year-end review to be published shortly in Nature Reviews Clinical Oncology, the SWOG 0777 study is identified as the major “practice changing” trial for 2016.